Alunbrig

Active Ingredient(s): Brigatinib
FDA Approved: * April 28, 2017
Pharm Company: * ARIAD
Category: Cancer

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc.[1] Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.[medical citation needed] Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.&am... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Alunbrig 90 mg Oral Tablet, Film Coated
NDC: 63020-090
Labeler:
Millennium Pharmaceuticals, Inc.
Alunbrig 30 mg Oral Tablet, Film Coated
NDC: 63020-113
Labeler:
Millennium Pharmaceuticals, Inc.
Alunbrig 180 mg Oral Tablet, Film Coated
NDC: 63020-180
Labeler:
Millennium Pharmaceuticals, Inc.
Alunbrig Kit
NDC: 63020-198
Labeler:
Millennium Pharmaceuticals, Inc.
Alunbrig 30 mg Oral Tablet, Coated
NDC: 76189-113
Labeler:
Ariad Pharmaceuticals Inc.